OPICAPONE
Get in touch with us!
An overview
ANTIPARKINSON THERAPY
Opicapone is used for adjunct therapy to levodopa and carbidopa in adult patients with Parkinson’s disease and end-of-dose motor fluctuations. It is a potent, reversible, and peripherally acting third-generation inhibitor of catechol-O-methyltransferase (COMT).
Description / use
- Product type: catechol-O-methyl transferase inhibitor.
- CAS number: 923287-50-7.
- Common indications: parkinson.
- Product status: development.
- Available grades: on demand.
PROPERTIES
- Oral administration.
- Long action duration (24 h).
- Potential global treatment candidates about 4-5 million people.
- CAGR (2023-2033) over +1.8%.
Advantages
Flow technology under development.
European manufacturer.
Total impurities around 0.1%.
Purity > 98%.
No monograph.
In compliance with general regulatory requirements.
Industrial quantities available in Q1 2026.
Strong commercial team globally distributed.
Competitive price based on market.
Final product innovator presentations
- 25 mg hard capsules.
- 50 mg hard capsules.
*Items covered by valid patents are not offered or supplied for commercial use. Products under patent are available for R&D use only.
Our API
Opicapone
- Our API opicapone is manufactured in accordance with cGMP and stringent international quality standards.
Quality
- Our quality control follows every stage from development of analytical methods to the control of manufacturing process, enabling us to achieve rigorous and stringent results in accordance with injectables parameters , even under aseptic conditions.
Samples availables
MINOCYCLINE
PATENT PROTECTION
